Sphingolipid Metabolism Rebalancing

Target: SMPD1 Composite Score: 0.455 Price: $0.52▲5.7% Citation Quality: Pending neurodegeneration Status: active
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
3
Opposing
Quality Report Card click to collapse
C
Composite: 0.455
Top 73% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.50 Top 76%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C+ Feasibility 12% 0.50 Top 65%
F Impact 12% 0.00 Top 50%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C+ Competition 6% 0.50 Top 77%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 3 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 0.92
Convergence
0.00 F 4 related hypothesis share this target

From Analysis:

Which specific metabolic pathways in APOE4+ microglia are most therapeutically tractable?

While APOE4 disrupts microglial metabolism broadly, the debate didn't identify which specific disrupted pathways offer the best therapeutic targets. This prioritization is needed for focused drug development efforts. Source: Debate session sess_SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 (Analysis: SDA-2026-04-04-gap-neuroinflammation-microglial-20260404)

→ View full analysis & debate transcript

Description

Target sphingomyelin phosphodiesterase or ceramide kinase to restore membrane fluidity and improve phagocytic function through membrane composition optimization

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.455 composite
8 citations 8 with PMID 8 medium Validation: 0% 5 supporting / 3 opposing
For (5)
5
3
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
4
MECH 3CLIN 1GENE 4EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Targeting glioblastoma signaling and metabolism wi…SupportingGENECell Rep MEDIUM2021-PMID:34731610-
The Niemann-Pick type diseases - A synopsis of inb…SupportingMECHProg Lipid Res MEDIUM2023-PMID:37003582-
Clinical, biochemical, and genotype-phenotype corr…SupportingGENEHum Mutat MEDIUM2021-PMID:33675270-
EDIL3/Del-1 prevents aortic dissection through enh…SupportingMECHAutophagy MEDIUM2024-PMID:38873925-
The Genetic Basis, Lung Involvement, and Therapeut…SupportingGENEBiomolecules MEDIUM2024-PMID:38397448-
The Niemann-Pick type diseases - A synopsis of inb…OpposingMECHProg Lipid Res MEDIUM2023-PMID:37003582-
Linking autism spectrum disorders and parkinsonism…OpposingGENEAnn Clin Transl… MEDIUM2023-PMID:36738194-
Acid sphingomyelinase as a pathological and therap…OpposingCLINExp Mol Med MEDIUM2024-PMID:38337058-
Legacy Card View — expandable citation cards

Supporting Evidence 5

Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. MEDIUM
Cell Rep · 2021 · PMID:34731610
The Niemann-Pick type diseases - A synopsis of inborn errors in sphingolipid and cholesterol metabolism. MEDIUM
Prog Lipid Res · 2023 · PMID:37003582
Clinical, biochemical, and genotype-phenotype correlations of 118 patients with Niemann-Pick disease Types A/B… MEDIUM
Clinical, biochemical, and genotype-phenotype correlations of 118 patients with Niemann-Pick disease Types A/B.
Hum Mutat · 2021 · PMID:33675270
EDIL3/Del-1 prevents aortic dissection through enhancing internalization and degradation of apoptotic vascular… MEDIUM
EDIL3/Del-1 prevents aortic dissection through enhancing internalization and degradation of apoptotic vascular smooth muscle cells.
Autophagy · 2024 · PMID:38873925
The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann-Pick Disease: A Comprehensive Review. MEDIUM
Biomolecules · 2024 · PMID:38397448

Opposing Evidence 3

The Niemann-Pick type diseases - A synopsis of inborn errors in sphingolipid and cholesterol metabolism. MEDIUM
Prog Lipid Res · 2023 · PMID:37003582
Linking autism spectrum disorders and parkinsonism: clinical and genetic association. MEDIUM
Ann Clin Transl Neurol · 2023 · PMID:36738194
Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's… MEDIUM
Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease.
Exp Mol Med · 2024 · PMID:38337058
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-09 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the knowledge gap and the enrichment data showing key microglial functions, here are my novel therapeutic hypotheses:

1. Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

APOE4 microglia exhibit disrupted mTOR signaling that locks them in a glycolytic state, preventing the metabolic flexibility needed for effective amyloid clearance. Targeting the TREM2-mTOR metabolic checkpoint could restore oxidative metabolism and enhance phagocytic capacity. Small molecule mTOR modulators specifically designed for CNS penetration could selectively reactivate oxidative phosphorylation

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll critically evaluate each hypothesis, focusing on weaknesses in the evidence and logic, alternative explanations, and missing key considerations.

1. Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

Specific Weaknesses:

  • Oversimplified causality: The hypothesis assumes APOE4 "locks" microglia in glycolysis, but metabolic states are highly dynamic and context-dependent
  • Missing cell-type specificity: TREM2 is expressed on multiple myeloid cells, not just microglia - CNS targeting claims are unsupported
  • Circular reasoning: Uses TREM2 enrichment as evidence f

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

UPDATED FEASIBILITY WITH CLINICAL DATA

TIER 1 TARGETS - IMMEDIATE COMMERCIAL VIABILITY

1. NAD+ Salvage Pathway (NAMPT/CD38) - HIGHEST PRIORITY

Clinical Validation:

  • NCT04430517: McLean Hospital studying NR in MCI/mild AD (n=50, active)
  • NCT05617508: Completed Phase 2 dose optimization (n=80, up to 3g daily)
  • NCT05040321: Brigham & Women's testing MIB-626 BBB penetration
  • NCT07278492: MIB-626 in Down syndrome (Alzheimer's model)
Competitive Landscape:
  • ChromaDex Corp: NIAGEN® (NR supplement) - $100M+ revenue
  • Elysium Health: BASI

Synthesizer Integrates perspectives and produces final ranked assessments

Based on the Theorist's hypotheses, Skeptic's critiques, and Expert's feasibility assessment, here is my synthesis with scored rankings:

Price History

0.460.490.52 0.54 0.43 2026-04-212026-04-252026-04-28 Market PriceScoreevidencedebate 8 events
7d Trend
Stable
7d Momentum
▲ 7.1%
Volatility
High
0.0527
Events (7d)
7

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (7)

No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
5

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.505

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for SMPD1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SMPD1 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (21)

APOE4CD38DGAT1MTORMTOR signalingNAD+ biosynthesisNAD+ levelsNAMPTSLC16A1SMPD1TREM2VDAC1amyloid clearancelactate transportlipid droplet formationmTOR modulatorsmetabolic flexibilitymitochondrial-ER contactsoxidative phosphorylationsirtuin function

Related Hypotheses

Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 | neurodegeneration
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.750 | neurodegeneration
SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation
Score: 0.732 | neurodegeneration
TREM2-ASM Crosstalk in Microglial Lysosomal Senescence
Score: 0.705 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (13 edges)

activates (2)

NAD+ biosynthesissirtuin functionAPOE4MTOR signaling

catalyzes (1)

DGAT1lipid droplet formation

causes (1)

APOE4lipid droplet formation

disrupts (1)

APOE4mitochondrial-ER contacts

enhances (1)

mTOR modulatorsoxidative phosphorylation

inhibits (2)

APOE4NAMPTCD38NAD+ levels

mediates (2)

TREM2amyloid clearanceSLC16A1lactate transport

regulates (3)

MTORmetabolic flexibilityVDAC1mitochondrial-ER contactsSMPD1sphingolipid metabolism

Mechanism Pathway for SMPD1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    NAD__biosynthesis["NAD+ biosynthesis"] -->|activates| sirtuin_function["sirtuin function"]
    TREM2["TREM2"] -->|mediates| amyloid_clearance["amyloid clearance"]
    APOE4["APOE4"] -.->|inhibits| NAMPT["NAMPT"]
    APOE4_1["APOE4"] -->|activates| MTOR_signaling["MTOR signaling"]
    MTOR["MTOR"] -->|regulates| metabolic_flexibility["metabolic flexibility"]
    APOE4_2["APOE4"] -->|causes| lipid_droplet_formation["lipid droplet formation"]
    DGAT1["DGAT1"] -->|catalyzes| lipid_droplet_formation_3["lipid droplet formation"]
    APOE4_4["APOE4"] -->|disrupts| mitochondrial_ER_contacts["mitochondrial-ER contacts"]
    VDAC1["VDAC1"] -->|regulates| mitochondrial_ER_contacts_5["mitochondrial-ER contacts"]
    SLC16A1["SLC16A1"] -->|mediates| lactate_transport["lactate transport"]
    SMPD1["SMPD1"] -->|regulates| sphingolipid_metabolism["sphingolipid metabolism"]
    mTOR_modulators["mTOR modulators"] -->|enhances| oxidative_phosphorylation["oxidative phosphorylation"]
    style NAD__biosynthesis fill:#81c784,stroke:#333,color:#000
    style sirtuin_function fill:#4fc3f7,stroke:#333,color:#000
    style TREM2 fill:#4fc3f7,stroke:#333,color:#000
    style amyloid_clearance fill:#4fc3f7,stroke:#333,color:#000
    style APOE4 fill:#ce93d8,stroke:#333,color:#000
    style NAMPT fill:#ce93d8,stroke:#333,color:#000
    style APOE4_1 fill:#ce93d8,stroke:#333,color:#000
    style MTOR_signaling fill:#81c784,stroke:#333,color:#000
    style MTOR fill:#4fc3f7,stroke:#333,color:#000
    style metabolic_flexibility fill:#4fc3f7,stroke:#333,color:#000
    style APOE4_2 fill:#ce93d8,stroke:#333,color:#000
    style lipid_droplet_formation fill:#4fc3f7,stroke:#333,color:#000
    style DGAT1 fill:#4fc3f7,stroke:#333,color:#000
    style lipid_droplet_formation_3 fill:#4fc3f7,stroke:#333,color:#000
    style APOE4_4 fill:#ce93d8,stroke:#333,color:#000
    style mitochondrial_ER_contacts fill:#4fc3f7,stroke:#333,color:#000
    style VDAC1 fill:#4fc3f7,stroke:#333,color:#000
    style mitochondrial_ER_contacts_5 fill:#4fc3f7,stroke:#333,color:#000
    style SLC16A1 fill:#4fc3f7,stroke:#333,color:#000
    style lactate_transport fill:#4fc3f7,stroke:#333,color:#000
    style SMPD1 fill:#4fc3f7,stroke:#333,color:#000
    style sphingolipid_metabolism fill:#81c784,stroke:#333,color:#000
    style mTOR_modulators fill:#4fc3f7,stroke:#333,color:#000
    style oxidative_phosphorylation fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 SMPD1 — PDB 5I73 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Which specific metabolic pathways in APOE4+ microglia are most therapeutically tractable?

neurodegeneration | 2026-04-08 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Lactate Shuttle Pathway Enhancement
Score: 0.46 · SLC16A1
Lipid Droplet Dynamics as Therapeutic Lever
Score: 0.46 · DGAT1
NAD+ Salvage Pathway Optimization
Score: 0.46 · NAMPT
Mitochondrial Contact Site Stabilization
Score: 0.46 · VDAC1
Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis
Score: 0.46 · MTOR
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.